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Abstract
Objective: The association of nonalcoholic fatty liver disease (NAFLD) with insulin
resistance and metabolic syndrome has been documented for obese men and middle-
aged men. This study was designed to determine the relationship between NAFLD and
the oral glucose tolerance test (OGTT) to predict preclinical diabetes in nondiabetic
young male patients (o30 years old). Methods: A total of 75 male patients who had
elevated liver enzymes and who were diagnosed with NAFLD were enrolled in this
study. A standard 75g OGTTwas carried out on all patients. Impaired fasting glucose
(IFG) and impaired glucose tolerance (IGT) were deﬁned as a fasting plasma glucose
(FPG) level Z100mg/dl but o126mg/dl, and a 2-h post-load glucose on the OGTTof
Z140mg/dl, but o200mg/dl respectively. Results: According to the OGTT results,
24 (32%) patients were diagnosed as having IGTand 12 (16%) patients were diagnosed
as having diabetes. Among the 48 patients with normal fasting glucose, 18 (37.6%)
patients showed abnormal glucose tolerance (15 had IGTand three had diabetes). The
NAFLD patients with abnormal glucose tolerance showed signiﬁcant differences in age,
weight, body mass index, waist–hip ratio, alanine aminotransferase, total bilirubin,
total cholesterol, low-density lipoprotein cholesterol, triglyceride, insulin, FPG and
homeostasis model for insulin resistance (HOMA-IR). Multiple regression analysis
showed that age, FPG and HOMA-IR wereindependent predictorsof abnormal glucose
tolerance. Conclusions: Although the patients were young men, an OGTT should be
recommended for NAFLD patients with elevated liver enzymes and IFG to predict the
risk of type 2 diabetes.
Nonalcoholic fatty liverdisease (NAFLD) covers awide range of
conditions from steatosis and nonalcoholic steatohepatitis
(NASH) to cirrhosis and liver failure. The prevalence of NAFLD
in western countries is at least 20% of the general population
and it is up to 70% for obese patients or those with type 2
diabetes mellitus (DM) (1–4). Because of the increasingly
westernized life style in Asian countries, NAFLD has become a
major cause of liver disease and its prevalence is estimated to be
up to 18% in Korea (5).
Nonalcoholic fatty liver disease is typically associated with
central obesity, DM, hypertension, dyslipidaemia and meta-
bolic syndrome (6–8). The pathogenic mechanism for NAFLD
has been explained by the ‘two-hit’ theory, which is as follow-
s:(i) accumulation of fat in hepatocytes and (ii) increased
hepatic oxidative stress (9). Insulin resistance promotes fatty
acid accumulation and oxidative stress (10). Ever since insulin
resistance was ﬁrst demonstrated in NAFLD patients (11),
subsequent reports have shown that insulin resistance plays a
key role in disease progression (12–14).
Patients with impaired glucose tolerance (IGT) and/or
impaired fasting glucose (IFG) are now considered as being
prediabetic, which indicates their relatively high risk for devel-
opingDM.IGTandIFGareassociatedwithmetabolicsyndrome
(15). It is important to identify patients with NAFLD
in the stage of preclinical diabetes or glucose intolerance because
they are at a high risk for developing DM and diabetes may be a
risk factor for the development of progressive ﬁbrosis (16).
The aim of this study was to evaluate the value of an oral
glucose tolerance test (OGTT), in order to diagnose preclinical
diabetes in nondiabetic young male NAFLD patients who are
below 30 years of age.
Materials and methods
Patients
The study was prospectivelyconductedfromApril2006 toApril
2007 at our institution. The study was approved by the
appropriate local ethics committees, and all patients provided
written informed consent before enrollment in the study. All
the enrolled patients who were referred to our outpatient clinic
showed an elevated alanine aminotransferase (ALT) level and a
fatty liver, as diagnosed by ultrasonography. Elevated ALT was
deﬁned as 440IU/L. The diagnosticcriteria for fattychange in
the liver by ultrasonography were as follows (17): (i) a diffuse
hyperechoic echotexture (bright liver), (ii) an increased liver
echotexture compared with the kidney, (iii) vascular blurring
and (iv) deep attenuation. Patients were excluded if they had a
history of viral hepatitis, alcohol intake of 30g or more per
week, use of medication known to cause hepatic steatosis such
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costeroid and a previous history of DM.
Clinical and laboratory analysis
The patients’ age andfamily histories of DMwererecorded. The
systolic and diastolic blood pressures were measured in the
sitting position after at least 10min of rest. During the 30min
preceding the measurement, subjects were required to refrain
from smoking or from consuming caffeine. The blood pressure
was measured twice and the mean value was recorded. Anthro-
pometric analysis included height, weight and body mass index
(BMI), and the latter was calculated as weight (kg) divided by
the square of the height (m
2). The waist–hip ratio (WHR) was
deﬁned as the waist circumference (cm) divided by the hip
circumference (cm). The waist and hip circumferences were
measured in the horizontal planes at the levels of the umbilicus
and the trochanter respectively. Laboratory analysis was per-
formed via standard laboratory methods. The serum biochem-
ical parameters included aspartate aminotransferase (AST),
ALT, total bilirubin, g-glutamyltransferase, alkaline amino-
transferase, total cholesterol, low-density lipoprotein cholester-
ol (LDL-C), high-density lipoprotein cholesterol (HDL-C),
triglyceride, fasting plasma glucose (FPG) and fasting insulin.
Serum biochemistries were performed with a Bayer model 1650
automated bio-analyzer (Bayer Diagnostic, Basingstoke, UK).
Serum insulin levels were measured with a solid-phase radio-
immunoassay (Diagnostic Products Corporation, Los Angeles,
CA, USA). The index of insulin resistance was calculated on the
basis of fasting glucose and insulin by the homeostasis model
for insulin resistance (HOMA-IR) (18).
Deﬁnitions of the metabolic syndrome and the abnormal
glucose tolerance test
Metabolic syndrome was deﬁned by the new International
Diabetes Federation deﬁnition (19): (i) Central obesity: waist
circumference of 90cm for Asian men and 80cm or more for
Asian women. (ii) Plus any two of four additional factors:
(A) Raised triglyceride: 4150mg/dl, or speciﬁc treatment of
this lipid abnormality. (B) Reduced HDL-C: o40mg/dl in
males and o50mg/dl in females, or speciﬁc treatment of this
lipid abnormality. (C) Raised blood pressure: systolic blood
pressure Z130 or diastolic blood pressure Z85mmHg, or
treatment of previously diagnosed hypertension. (D) Raised
FPG: 100mg/dl or more, or previously diagnosed type 2 DM.
All the patients underwent a 75g OGTT after an 8-h fast.
Blood samples were obtained from all patients ﬁve times during
the OGTT (before and 30, 60, 90 and 120min after oral glucose
loading). IFG and IGTwere deﬁned as an FPG level Z100mg/
dl but o126mg/dl, and a 2-h post-load glucose on the OGTT
of Z140mg/dl, but o200mg/dl respectively. DM was deﬁned
as a 2-h post-load glucose on the OGTTof 4200mg/dl (15).
The deﬁnition of abnormal glucose tolerance included IGT or
DM on the OGTT.
Statistical analysis
The measured values are presented as median (range), and
statistical analysis was performed using SPSS 11.0 (SPSS Inc.,
Chicago, IL, USA). Categorical variables were compared by the
w
2-test or Fisher’s exact test, whereas continuous variables were
compared by the Mann–Whitney U-test. Significant variables
from the univariate analysis were then subjected to multivariate
stepwise logistic regression analysis to identify any independent
significant factors associated with abnormal glucose tolerance
among NAFLD patients. Time courses of the mean glucose
concentrations during the OGTT were compared using
repeated measures at different time points (0, 30, 60, 90
and 120min). A P-value o0.05 was considered statistically
significant.
Results
A total of 75 patients were enrolled in this study. The patients
were all young (mean age: 23.53.7 years, range 19–30 years)
males and slightly overweight (the mean BMIwas 26.84.9kg/
m
2 and the range was 18–41kg/m
2). Twenty-seven (36%)
patients were diagnosed with IFG. According to the 75g OGTT,
24 (32%) patients were diagnosed as having IGTand 12 (16%)
patients were diagnosed as having diabetes. Among the 48
patients with normal fasting glucose, 18 (37.6%) patients
showed abnormal glucose tolerance (15 had IGTand three had
DM). The distribution of metabolic syndrome was 9/39
(23.1%) in normal OGTT, 6/24 (25%) in IGT and 9/12 (75%)
in DM respectively (Po0.05). The clinical characteristics of
the NAFLD patients with normal and abnormal OGTT
are presented in Table 1. Comparing the demographical and
anthropometrical variables, the patients with abnormal OGTT
results were older and their weight, BMI and WHR were also
signiﬁcantly higher than patients with a normal OGTT. The
biochemical analysis indicated that AST, ALT, total bilirubin,
total cholesterol, LDL-C, triglyceride, fasting glucose, fasting
insulin and HOMA-IR were signiﬁcantly higher in patients
with an abnormal OGTT. During the OGTT, signiﬁcant differ-
ences in the plasma glucose levels were seen at 0, 30, 60, 90 and
120min between the patients with a normal and an abnormal
OGTT respectively (Fig. 1). Further analysis using multiple
regression showed that age [odds ratio (OR): 2.172, 95%
conﬁdence interval (CI): 1.384–3.408], fasting glucose (OR:
1.197, 95% CI: 1.017–1.410) and HOMA-IR (OR: 3.374, 95%
CI: 1.497–8.064) turned out to be independent predictors of
abnormal glucose tolerance (Table 2).
Discussion
In the present study, we assessed, using the OGTT, for the early
diagnosis of DM in male NAFLD patients with an elevated ALT
level. Not many of our enrolled patients showed abnormal
responses on the OGTT. Sixteen per cent of the patients were
diagnosed with DM and 32% were diagnosed with IGT. The
relationship between abnormal glucose tolerance and NAFLD
has been established in several studies. A previous study of 73
patients (mean age: 458 years) with biopsy-proven NAFLD
showed that 33 and 29% of the patients had DM and IGT
respectively (20). Of 114 NAFLD patients (mean age:
53.610.5 years) who showed an elevated aminotransferase
level, 50 patients showed abnormal glucose tolerance (IGT or
DM) (21). In another study of 23 NAFLD patients, 3/13
patients (23.1%, mean age: 37.910.7 years) with abnormal
liver enzymes were diagnosed with IGT and only one patient
had DM, whereas none of the 10 patients with normal liver
enzymes showed 2-h post-load glucose levels Z140mg/dl on
the OGTT (22). As compared with the previous study, there
were little differences in the prevalence of undiagnosed DM or
IGT in the NAFLD patients. Yet the main difference in the
present study was the relatively young age of the patients (mean
age: 23.53.7 years, range: 19–30 years). Compared with the
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appear to have a higher risk of developing ﬁbrosis and cirrhosis
(10, 23, 24). Haukeland et al. (25) reported that abnormal
glucose tolerance was higher among patients with NASH
compared with patients with simple steatosis (72 vs. 49%) and
higher in NAFLD patients with ﬁbrosis compared with patients
without ﬁbrosis (76 vs. 49%). Therefore, in view of the high
prevalence of abnormal glucose tolerance after an OGTT even
in these young NAFLD patients, an early intervention for
NAFLD patients with IGT to prevent progression of DM and
hepatic ﬁbrosis would be needed.
Type 2 DM develops from an imbalance between insulin
sensitivity and insulin secretion. The earliest ﬁnding of type 2
Table 2. Predictors of abnormal glucose tolerance in nonalcoholic
fatty liver disease patients according to oral glucose tolerance test by
multivariate analysis
Variables Odds ratio 95% CI P value
Age (years) 2.172 1.384–3.408 0.001
Fasting glucose (mg/dl) 1.197 1.017–1.410 0.031
HOMA-IR 3.374 1.497–8.064 0.004
Multivariate logistic regression model adjusted for age, BMI, waist–hip
ratio, AST, ALT, total bilirubin, total cholesterol, LDL-cholesterol, triglycer-
ide, fasting glucose, fasting insulin and HOMA-IR.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,
body mass index; HOMA-IR, homeostasis model for insulin resistance;
LDL, low-density lipoprotein.
Table 1. Characteristics of the study populations according to the oral glucose tolerance test results
Variable NGT (n=39) IGTor diabetic GT (n=36) P value
Demographics
Age (years) 21 (19–26) 26 (19–30) o0.001
Family of DM (%) 18 (46.2) 18 (50) NS
Systolic BP (mmHg) 114 (97–148) 116 (101–159) NS
Diastolic BP (mmHg) 72 (65–90) 70 (62–88) NS
Metabolic syndrome (%) 9 (23.1) 15 (41.7) NS
Anthropometrics
Weight (kg) 76 (61–96) 85 (67–129) 0.015
Height (cm) 175 (164–183) 175 (167–183) NS
Body mass index (kg/m
2) 24 (21–34) 28 (18–41) 0.010
Waist circumference (cm) 86 (76–109) 92 (75–125) NS
Hip circumference (cm) 100 (95–114) 103 (80–125) NS
Waist–hip ratio 0.88 (0.77–0.95) 0.92 (0.78–1.00) 0.024
Biochemical
AST (IU/L) 44.5 (37–183) 60 (22–187) 0.024
ALT (IU/L) 84 (51–261) 117 (28–287) 0.001
T-bilirubin (mg/dl) 0.69 (0.41–1.64) 1.17 (0.71–2.23) o0.001
ALP (IU/L) 74 (57–120) 76.5 (58–122) NS
GGT (IU/L) 47 (16–149) 64.5 (20–134) NS
Total cholesterol (mg/dl) 206 (150–245) 219 (160–322) 0.013
LDL cholesterol (mg/dl) 123 (87–173) 134.5 (109–201) o0.001
HDL cholesterol (mg/dl) 43 (32–59) 38.5 (32–80) NS
Triglyceride (mg/dl) 140 (76–404) 197.5 (108–564) o 0.001
Oral glucose tolerance test (mg/dl)
0-h plasma glucose 86 (77–114) 100 (88–119) o0.001
120-min plasma glucose 110 (40–129) 155 (140–297) o0.001
Fasting glucose (mg/dl) 86 (77–114) 100 (88–119) o0.001
Fasting insulin (IU/ml) 8.2 (6.4–23.8) 13.85 (8.4–25.0) o0.001
HOMA-IR 1.81 (1.24–6.40) 3.28 (2.09–5.43) o0.001
The data were expressed as n (%) or median (range).
ALP, alkaline aminotransferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; GGT, g-glutamyl transferase; HDL,
high-density lipoprotein;HOMA-IR, homeostasis model for insulin resistance;IGT, impairedglucose tolerance; LDL,low-density lipoprotein;NGT,normal
glucose tolerance; NS, nonsigniﬁcant.
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Fig. 1. Time course of blood glucose levels during the oral glucose
tolerance test (OGTT) between normal glucose tolerance (NGT) and
impaired glucose tolerance/diabetic glucose tolerance. The mean
glucose concentrations during the OGTT between the two groups
were compared using repeated comparisons at different time points
(0, 30, 60, 90 and 120min). Data are presented as means with 95%
conﬁdence intervals. The differences of all time points (0, 30, 60, 90
and 120min) were statistically signiﬁcant respectively (Po0.05).
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termed insulin resistance (26). Insulin resistance is also a
common part of the pathophysiology of NAFLD. In our study,
an increased HOMA-IR, age and FPG were independent factors
associated with abnormal glucose tolerance in NAFLD patients
with elevated liver enzymes. Even the incidence of metabolic
syndrome was higher in abnormal OGTT (41.7%) than normal
OGTT (23.1%) but they did not show statistical signiﬁcance
(P=0.07). This result showed that NAFLD patients who were
diagnosed with IGTor type 2 DM were more insulin resistant
than the normal glucose tolerance group. IFG is determined by
an increased hepatic glucose output and by an insulin secretory
defect, but IGT is mostly associated with peripheral insulin
resistance and it is more strongly associated with the features of
metabolic syndrome than IFG (27). If the patients had combined
IGT and IFG, then the risk of subsequent DM was higher than
that for isolated IGTor isolated IFG. Because the prevalence of
IGTishigher thanthe prevalence of IFG in NAFLD patients with
elevated liver enzymes (28, 29), the OGTT can be used as a
routine procedure for detecting DM in younger patients.
One of the limitations of our study was the small sample size,
and we did not enrol a normal liver enzyme group. Therefore,
further study with sufﬁcient numbers of NAFLD patients
should be performed to provide generalized prognostic infor-
mation. Another limitation of our study was that the diagnosis
of NAFLD was based on ultrasonography, and this may have
overlookedthose patients with asmall amount of fatinﬁltration
of the liver. Ultrasonography is the most common method for
diagnosing NAFLD in clinical practice and it has a sensitivity
and a speciﬁcity of 94 and 84%, respectively (30, 31), but it
shows less sensitivity, particularly when the hepatic fat inﬁltra-
tion is o30% (32). However, a liver biopsy would have been
impossible to perform routinely in the present study because of
ethical problems.
In conclusion, the prevalence of abnormal glucose tolerance
was 48% in the enrolled Korean young male patients who
showed NAFLD and elevated liver enzymes. Although the study
patients were young men, OGTT should be recommended for
NAFLD patients with elevated liver enzymes and IFG to predict
their risk of type 2 diabetes.
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